Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study

Morciano, 2021, Excess mortality for care home residents during the first 23 weeks of the COVID-19 pandemic in England: a national cohort study, BMC Med, 19, 71, 10.1186/s12916-021-01945-2 Castro-Herrera, 2021, Relationships between age, frailty, length of care home residence and biomarkers of immunity and inflammation in older care home residents in the United Kingdom, Front Aging, 10.3389/fragi.2021.599084 Helfand, 2020, The exclusion of older persons from vaccine and treatment trials for coronavirus disease 2019—missing the target, JAMA Intern Med, 180, 1546, 10.1001/jamainternmed.2020.5084 Subbarao, 2021, Vaccine effectiveness against infection and death due to SARS-CoV-2, following one and two doses of the BNT162b2 and ChADox-1 in residents of long-term care facilities in England, using a time-varying proportional hazards model, SSRN, 10.2139/ssrn.3922678 Mazagatos, 2021, Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021, Euro Surveill, 26, 1, 10.2807/1560-7917.ES.2021.26.24.2100452 Monge, 2021, Direct and indirect effectiveness of mRNA vaccination against severe acute respiratory syndrome coronavirus 2 in long-term care facilities, Spain, Emerg Infect Dis, 27, 2595, 10.3201/eid2710.211184 Lefèvre, 2021, Beta SARS-CoV-2 variant and BNT162b2 vaccine effectiveness in long-term care facilities in France, Lancet Healthy Longev, 2, e685, 10.1016/S2666-7568(21)00230-0 Nanduri, 2021, MMWR Morb Mortal Wkly Rep, 70, 1163, 10.15585/mmwr.mm7034e3 Starrfelt, 2021, High vaccine effectiveness against COVID-19 infection and severe disease among residents and staff of long-term care facilities in Norway, November–June 2021, medRxiv Moustsen-Helms, 2021, Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA COVID-19 vaccine in long-term care facility residents and healthcare workers—a Danish cohort study, medRxiv Aldridge, 2021, Waning of SARS-CoV-2 antibodies targeting the spike protein in individuals post second dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and risk of breakthrough infections: analysis of the Virus Watch community cohort, medRxiv Levin, 2021, Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months, N Engl J Med, 385, e84, 10.1056/NEJMoa2114583 Wei, 2021, SARS-CoV-2 anti-spike IgG antibody responses after second dose of ChAdOx1 or BNT162b2 in the UK general population, medRxiv Pouwels, 2021, Effect of delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK, Nat Med, 27, 2127, 10.1038/s41591-021-01548-7 Goldberg, 2021, Waning immunity after the BNT162b2 vaccine in Israel, N Engl J Med, 385, e85, 10.1056/NEJMoa2114228 Andrews, 2022, Duration of protection against mild and severe disease by COVID-19 vaccines, N Engl J Med, 386, 340, 10.1056/NEJMoa2115481 Krutikov, 2021, Study protocol: understanding SARS-CoV-2 infection, immunity and its duration in care home residents and staff in England (VIVALDI), Wellcome Open Res, 5, 232, 10.12688/wellcomeopenres.16193.2 Chemaitelly, 2021, Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar, N Engl J Med, 385, e83, 10.1056/NEJMoa2114114 Tartof, 2021, Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study, Lancet, 398, 1407, 10.1016/S0140-6736(21)02183-8 Bar-On, 2021, Protection against COVID-19 by BNT162b2 booster across age groups, N Engl J Med, 385, 2421, 10.1056/NEJMoa2115926 Yavlinsky, 2022, Anti-spike antibody trajectories in individuals previously immunised with BNT162b2 or ChAdOx1 following a BNT162b2 booster dose, medRxiv Tut, 2021, Booster vaccination strongly enhances SARS-CoV-2-specific antibody and cellular responses in elderly residents of care homes, SSRN Electron J, 10.2139/ssrn.3990239 Muhsen, 2022, Effects of BNT162b2 COVID-19 vaccine booster in long-term care facilities in Israel, N Engl J Med, 386, 399, 10.1056/NEJMc2117385 Shrotri, 2021, Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study, Lancet Infect Dis, 21, 1529, 10.1016/S1473-3099(21)00289-9 Hernán, 2010, The hazards of hazard ratios, Epidemiology, 21, 13, 10.1097/EDE.0b013e3181c1ea43 Wolter, 2022, Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study, Lancet, 399, 437, 10.1016/S0140-6736(22)00017-4 Krutikov, 2022, Outcomes of SARS-CoV-2 omicron infection in residents of long-term care, medRxiv